Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Avril, N.
Right arrow Articles by Schwaiger, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Avril, N.
Right arrow Articles by Schwaiger, M.
Journal of Clinical Oncology, Vol 18, Issue 20 (October), 2000: 3495-3502
© 2000 American Society for Clinical Oncology

Breast Imaging With Positron Emission Tomography and Fluorine-18 Fluorodeoxyglucose: Use and Limitations

By N. Avril, C. A. Rosé, M. Schelling, J. Dose, W. Kuhn, S. Bense, W. Weber, S. Ziegler, H. Graeff, M. Schwaiger

From the Departments of Nuclear Medicine and Gynecology, Technische Universität München, Munich; and Department of Gynecology, University Hospital Eppendorf, Hamburg, Germany.

Address reprint requests to Norbert Avril, MD, Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Ismaningerstr 22, 81675 München, Germany; email n.avril{at}lrz.tu-muenchen.de

PURPOSE: To evaluate the diagnostic value of positron emission tomography (PET) using fluorine-18 fluorodeoxyglucose (FDG) for the diagnosis of primary breast cancer.

PATIENTS AND METHODS: Preoperatively, 144 patients with masses suggestive of breast cancer underwent PET imaging of the breast. To identify breast cancer by increased metabolic activity, parametric FDG-PET images were analyzed for increased tracer uptake applying conventional image reading (CIR) and sensitive image reading (SIR). One hundred eighty-five breast tumors were evaluated by histology, revealing 132 breast carcinomas and 53 benign masses.

RESULTS: Breast carcinomas were identified with an overall sensitivity of 64.4% (CIR) and 80.3% (SIR). The increase in sensitivity (SIR) resulted in a noticeable decrease in specificity, from 94.3% (CIR) to 75.5% (SIR). At stage pT1, only 30 (68.2%) of 44 breast carcinomas were detected, compared with 57 (91.9%) of 62 at stage pT2. A higher percentage of invasive lobular carcinomas were false-negative (65.2%) compared with invasive ductal carcinomas (23.7%). Nevertheless, positive PET scans provided a high positive-predictive value (96.6%) for breast cancer.

CONCLUSION: Partial volume effects and varying metabolic activity (dependent on tumor type) seem to represent the most significant limitations for the routine diagnostic application of PET. The number of invasive procedures is therefore unlikely to be significantly reduced by PET imaging in patients presenting with abnormal mammography. However, the high positive-predictive value, resulting from the increased metabolic activity of malignant tissue, may be used with carefully selected subsets of patients as well as to determine the extent of disease or to assess therapy response.




This article has been cited by other articles:


Home page
 Am. J. Roentgenol.Home page
M. Imbriaco, M. G. Caprio, G. Limite, L. Pace, T. De Falco, E. Capuano, and M. Salvatore
Dual-Time-Point 18F-FDG PET/CT Versus Dynamic Breast MRI of Suspicious Breast Lesions
Am. J. Roentgenol., November 1, 2008; 191(5): 1323 - 1330.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
T. A. Heusner, S. Kuemmel, L. Umutlu, A. Koeninger, L. S. Freudenberg, E. A.M. Hauth, K. R. Kimmig, M. Forsting, A. Bockisch, and G. Antoch
Breast Cancer Staging in a Single Session: Whole-Body PET/CT Mammography
J. Nucl. Med., August 1, 2008; 49(8): 1215 - 1222.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Mahner, S. Schirrmacher, W. Brenner, L. Jenicke, C. R. Habermann, N. Avril, and J. Dose-Schwarz
Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer
Ann. Onc., July 1, 2008; 19(7): 1249 - 1254.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. Basu and A. Alavi
Feasibility of Automated Partial-Volume Correction of SUVs in Current PET/CT Scanners: Can Manufacturers Provide Integrated, Ready-to-Use Software?
J. Nucl. Med., June 1, 2008; 49(6): 1031 - 1032.
[Full Text] [PDF]

Home page
 JAMAHome page
S. Masciari, A. D. Van den Abbeele, L. R. Diller, I. Rastarhuyeva, J. Yap, K. Schneider, L. Digianni, F. P. Li, J. F. Fraumeni Jr, S. Syngal, et al.
F18-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography Screening in Li-Fraumeni Syndrome
JAMA, March 19, 2008; 299(11): 1315 - 1319.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. C. Hodgson and K. Y. Gulenchyn
Is There a Role for Positron Emission Tomography in Breast Cancer Staging?
J. Clin. Oncol., February 10, 2008; 26(5): 712 - 720.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
D. J. A. Margolis, J. M. Hoffman, R. J. Herfkens, R. B. Jeffrey, A. Quon, and S. S. Gambhir
Molecular Imaging Techniques in Body Imaging
Radiology, November 1, 2007; 245(2): 333 - 356.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
H. S. Lim, W. Yoon, T. W. Chung, J. K. Kim, J. G. Park, H. K. Kang, H. S. Bom, and J. H. Yoon
FDG PET/CT for the Detection and Evaluation of Breast Diseases: Usefulness and Limitations
RadioGraphics, October 1, 2007; 27(suppl_1): S197 - S213.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B Vincenzi, A Calvieri, D Santini, V Altomare, and G Tonini
Occasional FDG PET recognition of in situ breast cancer
Ann. Onc., September 1, 2007; 18(9): 1584 - 1585.
[Full Text] [PDF]

Home page
 RadiologyHome page
C. K. Kuhl
Current Status of Breast MR Imaging * Part 2. Clinical Applications
Radiology, September 1, 2007; 244(3): 672 - 691.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
C. Kuhl
The Current Status of Breast MR Imaging * Part I. Choice of Technique, Image Interpretation, Diagnostic Accuracy, and Transfer to Clinical Practice
Radiology, August 1, 2007; 244(2): 356 - 378.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. Mavi, T. F. Cermik, M. Urhan, H. Puskulcu, S. Basu, J. Q. Yu, H. Zhuang, B. Czerniecki, and A. Alavi
The Effects of Estrogen, Progesterone, and C-erbB-2 Receptor States on 18F-FDG Uptake of Primary Breast Cancer Lesions
J. Nucl. Med., August 1, 2007; 48(8): 1266 - 1272.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
L. Moy, F. Ponzo, M. E. Noz, G. Q. Maguire Jr., A. D. Murphy-Walcott, A. E. Deans, M. T. Kitazono, L. Travascio, and E. L. Kramer
Improving Specificity of Breast MRI Using Prone PET and Fused MRI and PET 3D Volume Datasets
J. Nucl. Med., April 1, 2007; 48(4): 528 - 537.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
T. M. Blodgett, C. C. Meltzer, and D. W. Townsend
PET/CT: Form and Function
Radiology, February 1, 2007; 242(2): 360 - 385.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Rousseau, A. Devillers, C. Sagan, L. Ferrer, B. Bridji, L. Campion, M. Ricaud, E. Bourbouloux, I. Doutriaux, M. Clouet, et al.
Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [18F]Fluorodeoxyglucose Positron Emission Tomography
J. Clin. Oncol., December 1, 2006; 24(34): 5366 - 5372.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. Mavi, M. Urhan, J. Q. Yu, H. Zhuang, M. Houseni, T. F. Cermik, D. Thiruvenkatasamy, B. Czerniecki, M. Schnall, and A. Alavi
Dual Time Point 18F-FDG PET Imaging Detects Breast Cancer with High Sensitivity and Correlates Well with Histologic Subtypes
J. Nucl. Med., September 1, 2006; 47(9): 1440 - 1446.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
A. Chung, D. Liou, S. Karlan, A. Waxman, K. Fujimoto, M. Hagiike, and E. H. Phillips
Preoperative FDG-PET for Axillary Metastases in Patients With Breast Cancer
Arch Surg, August 1, 2006; 141(8): 783 - 789.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. E. Juweid, G. A. Wiseman, J. M. Vose, J. M. Ritchie, Y. Menda, J. E. Wooldridge, F. M. Mottaghy, E. M. Rohren, N. M. Blumstein, A. Stolpen, et al.
Response Assessment of Aggressive Non-Hodgkin's Lymphoma by Integrated International Workshop Criteria and Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography
J. Clin. Oncol., July 20, 2005; 23(21): 4652 - 4661.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Quon and S. S. Gambhir
FDG-PET and Beyond: Molecular Breast Cancer Imaging
J. Clin. Oncol., March 10, 2005; 23(8): 1664 - 1673.
[Full Text] [PDF]

Home page
 Ann OncolHome page
S.-J. Kim, S.-k. Kim, E. S. Lee, J. Ro, and S. h. Kang
Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy
Ann. Onc., September 1, 2004; 15(9): 1352 - 1357.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. Boellaard, N. C. Krak, O. S. Hoekstra, and A. A. Lammertsma
Effects of Noise, Image Resolution, and ROI Definition on the Accuracy of Standard Uptake Values: A Simulation Study
J. Nucl. Med., September 1, 2004; 45(9): 1519 - 1527.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
P. J. Lovrics, V. Chen, G. Coates, S. D. Cornacchi, C. H. Goldsmith, C. Law, M. N. Levine, K. Sanders, and V. R. Tandan
A Prospective Evaluation of Positron Emission Tomography Scanning, Sentinel Lymph Node Biopsy, and Standard Axillary Dissection for Axillary Staging in Patients with Early Stage Breast Cancer
Ann. Surg. Oncol., September 1, 2004; 11(9): 846 - 853.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
E. M. Rohren, T. G. Turkington, and R. E. Coleman
Clinical Applications of PET in Oncology
Radiology, May 1, 2004; 231(2): 305 - 332.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. J.M. van der Hoeven, N. C. Krak, O. S. Hoekstra, E. F.I. Comans, R. P.A. Boom, D. van Geldere, S. Meijer, E. van der Wall, J. Buter, H. M. Pinedo, et al.
18F-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Staging of Locally Advanced Breast Cancer
J. Clin. Oncol., April 1, 2004; 22(7): 1253 - 1259.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. L. Wahl, B. A. Siegel, R. E. Coleman, and C. G. Gatsonis
Prospective Multicenter Study of Axillary Nodal Staging by Positron Emission Tomography in Breast Cancer: A Report of the Staging Breast Cancer With PET Study Group
J. Clin. Oncol., January 15, 2004; 22(2): 277 - 285.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
U. Guller, E. Nitzsche, H. Moch, and M. Zuber
Is Positron Emission Tomography an Accurate Non-invasive Alternative to Sentinel Lymph Node Biopsy in Breast Cancer Patients?
J Natl Cancer Inst, July 16, 2003; 95(14): 1040 - 1043.
[Full Text] [PDF]

Home page
 RadioGraphicsHome page
L. Kostakoglu, H. Agress Jr, and S. J. Goldsmith
Clinical Role of FDG PET in Evaluation of Cancer Patients
RadioGraphics, March 1, 2003; 23(2): 315 - 340.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
L. Kostakoglu and S. J. Goldsmith
18F-FDG PET Evaluation of the Response to Therapy for Lymphoma and for Breast, Lung, and Colorectal Carcinoma
J. Nucl. Med., February 1, 2003; 44(2): 224 - 239.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
E. A. Levine, R. I. Freimanis, N. D. Perrier, K. Morton, N. M. Lesko, S. Bergman, K. R. Geisinger, R. C. Williams, C. Sharpe, V. Zavarzin, et al.
Positron Emission Mammography: Initial Clinical Results
Ann. Surg. Oncol., January 1, 2003; 10(1): 86 - 91.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
L. A. Newman, A. U. Buzdar, S. E. Singletary, H. M. Kuerer, T. Buchholz, F. C. Ames, M. I. Ross, and K. K. Hunt
A Prospective Trial of Preoperative Chemotherapy in Resectable Breast Cancer: Predictors of Breast-Conservation Therapy Feasibility
Ann. Surg. Oncol., April 1, 2002; 9(3): 228 - 234.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Bos, J. J.M. van der Hoeven, E. van der Wall, P. van der Groep, P. J. van Diest, E. F.I. Comans, U. Joshi, G. L. Semenza, O. S. Hoekstra, A. A. Lammertsma, et al.
Biologic Correlates of 18Fluorodeoxyglucose Uptake in Human Breast Cancer Measured by Positron Emission Tomography
J. Clin. Oncol., January 15, 2002; 20(2): 379 - 387.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
N. Avril, M. Menzel, J. Dose, M. Schelling, W. Weber, F. Janicke, W. Nathrath, and M. Schwaiger
Glucose Metabolism of Breast Cancer Assessed by 18F-FDG PET: Histologic and Immunohistochemical Tissue Analysis
J. Nucl. Med., January 1, 2001; 42(1): 9 - 16.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2000 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online